Business
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
– ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders – – Topline Data Expected Mid-Year 2025 – MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the last patient in the ATH434-202 Phase 2 trial has completed the study. The ATH434-202 is an
About this update from Alterity Therapeutics Ltd.
[{"type":"image","alt":"ALTERITY THERAPEUTICS LIMITED","displaySize":"","headline":null,"caption":"ALTERITY THERAPEUTICS LIMITED","className":"","disableSlideshowImg":false,"size":{"original":{"width":222,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/5761c8df20b76a3904e54a7775315c62"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aH_lC7vKS4YC2ZvHbgCTDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5761c8df20b76a3904e54a7775315c62","width":222,"height":56}},"lazy":false},{"type":"text","content":"– ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders –","length":81,"tagName":"p"},{"type":"text","content":"– Topline Data Expected Mid-Year 2025 –","length":39,"tagName":"p"},{"type":"text","content":"MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the last patient in the ATH434-202 Phase 2 trial has completed the study. The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA).","length":539,"tagName":"p"},{"type":"text","content":"“Following the positive results from our randomized, double-blind Phase 2 trial1, we are pleased to announce that the last participant has now completed all clinical evaluations in our open-label study of advanced MSA,” said David Stamler, M.D., Chief Executive Officer of Alterity. “The 202 study gives us the opportunity to evaluate the effects of ATH434 treatment in a population that faces severe challenges due to the stage of their illness. The data from this study will help guide our development program given the differences between the 202 study and the double-blind trial. I greatly appreciate the contributions of the trial participants and thank them for their participation. We look forward to reporting topline data from this study in mid-year 2025.”","length":765,"tagName":"p"},{"type":"text","content":"About ATH434-202 Phase 2 Clinical Trial ","length":39,"tagName":"p"},{"type":"text","content":"The ATH434-202 Phase 2 clinical trial is an open label study, entitled “A Biomark...